|Dr. Timothy C. Rodell||Interim CEO & Director||392.24k||N/A||1951|
|Mr. James B. Frakes||CFO, Sr. VP of Fin. & Sec.||255.83k||N/A||1957|
|Mr. James A. Joyce||Consultant||393.25k||N/A||1962|
|Mr. Sunil Sawhney||Head of Clinical Studies||N/A||N/A||N/A|
|Dr. Richard H. Tullis||Consultant||N/A||N/A||1945|
Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. The company is based in San Diego, California.
Aethlon Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.